In the pathological condition of psoriasis, systemic IL‐17A elevation can trigger microglia activation, provoke pro‐inflammation mediators to release, evoke neuroinflammation, subsequently inhibit hippocampal neurogenesis, and result in depression. Here, IL17A is linked to depressive symptom measurement.